Piramal Pharma has reduced its raw material sourcing from China to single-digit levels to lower supply chain risks. The company reported 28% revenue growth in the second quarter and is now preparing for the upcoming exit of its distribution contract with Bayer.
Piramal Pharma has significantly reduced its reliance on China for raw materials, bringing its procurement spending on Chinese goods down to single-digit percentages. The company stated this is a strategic move to insulate its supply chain from potential geopolitical issues. Rather than focusing on immediate cost savings, the management emphasized that this shift is intended to provide long-term operational stability for clients by diversifying sourcing across India, the United Kingdom, and the United States.
The company’s recent performance highlights a strong growth phase, with revenue rising 28% year-on-year to ₹2,617 crore in the second quarter. Following these results, the company has updated its revenue growth guidance for the 2027 fiscal year to between 19% and 20%. A key part of this performance strategy is shifting the business model toward more complex products, such as specialized injections and high-potency drugs, which typically offer better profit margins than standard, commodity-like pharmaceutical products.
Investors should note that the company is bracing for a major structural change in its distribution business. The long-standing distribution agreement with Bayer is set to expire this December. Historically, this partnership contributed ₹475 crore to the company's annual revenue. While this represents a noticeable reduction in the top-line, management maintains that the impact on overall profitability will be negligible because the Bayer business operated on thin profit margins. To fill this gap, the company plans to focus on scaling its proprietary brands within its consumer healthcare division.
On the product strategy front, the company is doubling down on niche areas like complex peptides. Interestingly, it has confirmed that it does not intend to enter the highly competitive and capital-intensive GLP-1 drug market at this time. This suggests a focus on maintaining balance sheet discipline rather than chasing every new trend in the biotech sector.
The most important monitorable for investors in the coming quarters will be how the consumer healthcare division performs as it attempts to offset the loss of revenue from the Bayer contract. Additionally, as the company shifts its manufacturing reliance away from China, investors may want to track whether there is any short-term pressure on operating margins due to the potential cost of setting up alternative supply chains.